November 16th, 2026Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRCOnvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.Read more
November 12th, 2026GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.Read more
November 8th, 2026Five Under 5: Top Oncology Videos for the Week of 11/1The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.Read more
November 6th, 2026Canakinumab Reduces Nodule Size in High-Risk Lung PrecancersIL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.Read more
November 18th, 2026Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLCThe FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.Read more
November 18th, 2026Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future CareersDeepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.Read more
November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 18th, 2026Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLCLonger follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.Read more